McAfee Receives AV-Comparatives Gold Awards for Best Real-World Protection and Best Performance Throughout 2024
20.1.2025 14:00:00 CET | Business Wire | Press release
Coveted awards celebrate McAfee for providing powerful malware protection without slowing down PCs
McAfee, a global online protection leader, today announced that it has been recognized by AV-Comparatives with both the ‘Real-World Protection Gold Award’ and the ‘Best Overall Speed Gold Award’. These honors spotlight McAfee’s unmatched ability to deliver top-tier malware protection to consumers while improving PC performance, as demonstrated in AV-Comparatives’ 2024 test results.
McAfee was one of only six vendors to achieve top overall results in the 2024 Real-World Protection tests, while also ranking as the vendor with the lowest impact on PC performance throughout 2024. This means that by replacing the protection that comes with your PC’s operating system, McAfee can improve the overall performance of a PC.
This is particularly important at a time when bad actors are leveraging rapidly evolving and increasingly sophisticated tools to target victims.
Throughout the year, the AV-Comparatives Lab team rigorously tests leading consumer security products and evaluates them in terms of protection, and impact on PC performance.
- McAfee’s win in the Real-World Protection Test points to an ability to offer exceptional malware protection in everyday online conditions, as tested by AV-Comparatives. This recognition highlights McAfee’s success in providing a high level of protection with minimal false alarms; this ensures consumers are protected without the burden of discerning whether or not something is harmful.
- McAfee’s top rank in the PC Performance Test reflects its strength, as tested by AV-Comparatives, in delivering powerful security without slowing down system performance. This critical metric aligns with McAfee’s consumer-first focus, ensuring that consumers stay protected while their PCs run efficiently at top speed.
“We are honored to receive both the Best Real-World Protection and the Best PC Performance awards,” said Steve Grobman, Chief Technology Officer, McAfee. “AV-Comparatives’ trusted analysis validates our success in developing technology that protects people while improving device performance. We are committed to giving consumers the education and tools they need to stay safe online while maintaining performance and ensuring that our protection evolves as quickly as the threat landscape.”
Those interested in protecting themselves and their families online with this year’s top-rated security software can download a free trial of McAfee Total Protection. This includes the company’s award-winning anti-malware technology, as well as scam detection, social privacy management, identity monitoring, Secure VPN, password management, and safe browsing capabilities for all-in-one protection.
McAfee’s award-winning, AI-powered anti-malware technology is included in McAfee Total Protection, McAfee+ Premium, McAfee+ Advanced, and McAfee+ Ultimate.
You can learn more about McAfee’s awards and recognition from AV-Comparatives here.
About McAfee
McAfee Corp. is a global leader in online protection for consumers. Focused on protecting people, not just devices, McAfee’s consumer solutions adapt to users’ needs in an always online world, empowering them to live securely through integrated, intuitive solutions that protect their families, communities, and businesses with the right security at the right moment. For more information, please visit https://www.McAfee.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250120474901/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA® (levodopa inhalation powder) in Mainland China, Hong Kong and Macao26.5.2026 09:00:00 CEST | Press release
Kvvit to lead local development, regulatory activities and commercialization of INBRIJA® in mainland China, Hong Kong and Macao Under the agreement, Merz Therapeutics will receive upfront, development and commercial milestone payments, and tiered supply and royalty arrangements, with no manufacturing rights granted to Kvvit Merz Therapeutics GmbH and Jiangxi Kvvit Pharmaceutical Co. Ltd. today announced that the companies have entered into an exclusive license and collaboration agreement regarding INBRIJA® (levodopa inhalation powder) and its proprietary inhalation device for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor in mainland China, Hong Kong and Macao. Under the agreement, Merz will supply INBRIJA® and retain responsibility for global product quality and key regulatory activities. Kvvit will lead development, regulatory activities and commercializat
Poland’s Poznan University of Technology Unveils IQM Quantum Computer to Drive Research and Education26.5.2026 08:49:00 CEST | Press release
IQM Radiance R1 is the first on-premises quantum computer for the PUT. The university aims to use the system to spearhead quantum education and research while boosting STEM in the country. This is the second operational quantum computer deployed in Poland by IQM. The university recognizes the significant long-term potential of integrating quantum computing, artificial intelligence, and high-performance computing (HPC), and intends to play a key role in shaping this transformation in Europe. Poznan University of Technology (PUT) has launched its first locally installed quantum computer, deployed by IQM Quantum Computers, to advance education and scientific research in the field of quantum technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525424085/en/ The moment Poland switched on IQM's second quantum computer. Minister of Science and Higher Education Dr. Marcin Kulasek, IQM CEO Jan Goetz and CCO Sylwia de Weyde
BearingPoint Introduces Fully Sovereign On-Premise Infrastructure for GenAI and Agentic AI in Europe26.5.2026 08:30:00 CEST | Press release
BearingPoint is expanding its AI portfolio with a fully owned, sovereign on-premise and edge infrastructure designed specifically for generative and agentic AI workloads in highly regulated industries and public administrations in Europe. Building on decades of experience operating its own sovereign cloud, the firm now offers clients both dedicated hardware and token-based access to large language models – fully GDPR-compliant, ISO-certified and, on request, NIS2- and DORA-ready BearingPoint announces the launch of the BearingPoint Fully-Owned Sovereign Infrastructure Stack, an infrastructure platform designed, operated, and managed entirely by BearingPoint for GenAI and agentic AI applications, consistently engineered for European sovereignty, compliance, and security. With its own data center in Graz, the solution enables companies and public institutions to run sensitive AI workloads in fully controlled, EU-based environments – from initial innovation projects to mission-critical sc
Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s26.5.2026 08:00:00 CEST | Press release
Study Topline results will be released around the end of Q2 2026 BIA 28-6156 is being developed as a potential first-in-class disease-modifying therapy in GBA-PD Bial was present at the GBA1 conference and is currently attending the World Parkinson Congress Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced the completion of the treatment period in its Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). Upon completion of the 78-week double-blind treatment period and all scheduled safety follow-ups, data cleaning and analysis are currently ongoing. Topline results will be released around the end of Q2. A status report on the ACTIVATE study was presented in an oral presentation at the 3rd International GBA1 Meeting 2026. The team is currently attending the 7th World Parkinson Congress, taking place in Pho
Oticon Medical Introduces Ponto™ Instant, Expanding Non-Surgical Choice with Instant HearBand and Instant SoundConnector26.5.2026 07:00:00 CEST | Press release
Oticon Medical today announces its new non-surgical portfolio, Ponto Instant, designed to broaden access to bone conduction hearing and offer more choice for users and hearing care professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525771593/en/ Left: Instant HearBand, a discreet behind-the-head wearable solution that offers an alternative to Softband 5. Right: Instant SoundConnector, a small accessory fitted to a cap or other headwear, providing another non-surgical way to wear a Ponto sound processor. The Ponto Instant portfolio includes Softband 5, Oticon Medical’s established and trusted non-surgical solution, and now expands with the launch of Instant HearBand and Instant SoundConnector, further strengthening its wearable offering for children and adults who prefer a non-surgical solution. Instant HearBand: a discreet new wearable alternative As part of the new portfolio, Instant HearBand is introduced as
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom